Norlase Leaf laser receives CE mark approval

Article

Distribution to begin in the European Union.

Norlase has been granted the European CE mark for its Leaf laser, following a 510(l)-market clearance by the US Food and Drug Administration (FDA) and ISO 13485:2016 certification. This approval will allow the company to market and distribute its fiberglass, green laser for the treatment of retina and glaucoma diseases in the European Union and other countries that recognize the European standard.

Related: CooperVision produces hand sanitizer at manufacturing sites

“This marks another significant milestone as we continue our mission to improve practice efficiency and workflow for ophthalmologists and equip them with the tools to provide quality eye care for patients worldwide,” said Oliver Hvidt, Norlase president, in a statement.

The Leaf laser photocoagulator allows ophthalmologists to perform laser therapy with minimal set-up time and physical space because it attaches to an existing slit lamp. It connects to a wireless tablet as its user interface and offers voice control features. Physicians can operate it touch-free.

Related: Allergan receives FDA complete response letter for wet AMD therapy

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Ramsey discusses innovation for your eye care practice at EyeCon 2024
Dr. Leonard Messner at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
EyeCon 2024: Insights on transforming ocular surface disease management
© 2024 MJH Life Sciences

All rights reserved.